Radiation dosimetry of whole-body dual-tracer 18F-FDG and 11C-acetate PET/CT for hepatocellular carcinoma Journal Article
| Authors: | Liu, D.; Khong, P. L.; Gao, Y.; Mahmood, U.; Quinn, B.; St Germain, J.; Xu, X. G.; Dauer, L. T. |
| Article Title: | Radiation dosimetry of whole-body dual-tracer 18F-FDG and 11C-acetate PET/CT for hepatocellular carcinoma |
| Abstract: | Combined whole-body dual-tracer (18F-FDG and 11C-acetate) PET/ CT is increasingly used for staging hepatocellular carcinoma, with only limited studies investigating the radiation dosimetry data of these scans. The aim of the study was to characterize the radiation dosimetry of combined whole-body dual-tracer PET/CT protocols. Methods: Consecutive adult patients with hepatocellular carcinoma who underwent whole-body dual-tracer PET/CT scans were retrospectively reviewed with institutional review board approval. OLINDA/EXM 1.1 was used to estimate patient-specific internal dose exposure in each organ. Biokinetic models for 18F-FDG and 11C-acetate as provided by ICRP (International Commission on Radiological Protection) publication 106 were used. Standard reference phantoms were modified to more closely represent patientspecific organ mass. With patient-specific parameters, organ equivalent doses from each CT series were estimated using Virtual- Dose. Dosimetry capabilities for tube current modulation protocols were applied by integrating with the latest anatomic realistic models. Effective dose was calculated using ICRP publication 103 tissueweighting coefficients for adult male and female, respectively. Results: Fourteen scans were evaluated (12 men, 2 women; mean age ± SD, 60 ± 19.48 y). The patient-specific effective dose from 18F-FDG and 11C-acetate was 6.08 ± 1.49 and 1.56 ± 0.47 mSv, respectively, for male patients and 6.62 ± 1.38 and 1.79 ± 0.12 mSV, respectively, for female patients. The patient-specific effective dose of the CT component, which comprised 2 noncontrast whole-body scans, to male and female patients was 21.20 ± 8.94 and 14.79 ± 3.35 mSv, respectively. Thus, the total effective doses of the combined whole-body dual-tracer PET/CT studies for male and female patients were 28.84 ± 10.18 and 23.19 ± 4.61 mSv, respectively. Conclusion: Patient-specific parameters allow for more accurate estimation of organ equivalent doses. Considering the substantial radiation dose incurred, judicious medical justification is required with every whole-body dual-tracer PET/CT referral. Although radiation risks may have less impact for the population with cancer because of their reduced life expectancy, the information is of interest and relevant for both justification, to evaluate risk/benefit, and protocol optimization. COPYRIGHT © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc. |
| Keywords: | radiation exposure; ct; pet/ct; dual tracer; effective dose |
| Journal Title: | Journal of Nuclear Medicine |
| Volume: | 57 |
| Issue: | 6 |
| ISSN: | 0161-5505 |
| Publisher: | Society of Nuclear Medicine |
| Date Published: | 2016-06-01 |
| Start Page: | 907 |
| End Page: | 912 |
| Language: | English |
| DOI: | 10.2967/jnumed.115.165944 |
| PROVIDER: | scopus |
| PUBMED: | 26823568 |
| PMCID: | PMC5556938 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 July 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
170Dauer -
61St Germain -
20Quinn -
46Mahmood
Related MSK Work